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Abstract
Background: Exposure to Leishmania induces a humoral immune response that can be used as a marker of parasite
exposure.
Methodology/Principal Findings: Herein, ELISA was used to screen sera from patients with Tegumentary Leishmaniasis (TL)
against different L. infantum-chagasi-derived recombinant proteins (rHSP70, rH2A, rH2B, rH3, rH4 and rKMP11). Among the
recombinant proteins, rHSP70 and rH2A showed the best reactivity against human sera obtained from endemic areas of TL.
Receiver-Operator Characteristics (ROC) curve analysis was used to identify the effectiveness of these proteins for
serodiagnosis of TL. ROC curves confirmed the superior performance of rHSP70 and rH2A, in comparison to the other tested
recombinant proteins. Additionally, we evaluated the specificity of the response to rHSP70 and rH2A by testing sera
obtained from patients with Chagas’ disease, Tuberculosis, Leprosy or Systemic Lupus Erythematosus. In this case, rHSP70
displayed an increased ability to discriminate diseases, in comparison to SLA.
Conclusion: Our results raise possibility of using rHSP70 for the serodiagnosis of TL
Citation: Souza AP, Soto M, Costa JML, Boaventura VS, de Oliveira CI, et al. (2013) Towards a More Precise Serological Diagnosis of Human Tegumentary
Leishmaniasis Using Leishmania Recombinant Proteins. PLoS ONE 8(6): e66110. doi:10.1371/journal.pone.0066110
Editor: Dario S. Zamboni, University of Sa˜o Paulo, Brazil
Received September 20, 2012; Accepted May 7, 2013; Published June 12, 2013
Copyright:  2013 Souza et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research and publication process was supported by grants from from Pronex: CNPq/FAPESB. This study was in part supported in Spain by grant FIS
PI11/00095 from Ministerio de Economı´a y Competitividad. APS received fellowship from CNPq. JML, CIO, MB-N and AB are senior investigators from CNPq. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: abarral@bahia.fiocruz.br
Introduction
The success of Leishmaniasis treatment depends on an effective
and early diagnosis. Currently, diagnosis of Tegumentary Leish-
maniasis (TL) is often performed based on clinical and epidemi-
ological data associated with the results of different laboratory
tests. Parasitological diagnosis is highly specific as it demonstrates
the presence of the parasite by immuno-staining of biopsy tissues,
by PCR amplification of parasite DNA or, ultimately, by
cultivation of biopsy material allowing for parasite growth or for
experimental inoculation into susceptible laboratory animals [1–
11]. These methods have high specificity, but sensitivity is subject
to variation because the tissue distribution of parasites is not
homogeneous [6–8]. Moreover, parasitological tests require
invasive procedures and depend on restrictive conditions for the
collection of material which limit their use in large-scale
epidemiological studies. Due to these reasons, indirect tests, based
on the host immune response are of utmost importance.
Sera from Leishmaniasis patients are routinely collected for
laboratory evaluation of several parameters and serological tests
for infectious diseases are easy to perform. Despite new
approaches for immunodiagnosis [12], the Enzyme-Linked
Immunosorbent Assay (ELISA) has been the most widely used
serological method for Leishmaniasis diagnosis as it is easy to
perform and has a low cost (reviewed in [13]). In addition, this
method can be performed in intermediate level laboratories using
relatively simple equipment [13]. ELISA is commonly used to
diagnose visceral leishmaniasis (VL) and has a higher sensitivity for
TL diagnosis than parasitological tests (reviewed by [6] and [14]).
Crude Leishmania antigen preparations, also known as soluble
Leishmania antigen (SLA), are the most commonly parasite proteins
employed in ELISA for Leishmaniasis diagnosis. Although the
techniques performed with SLA have high sensitivity, they lack
specificity. Use of SLA and occurrence of false positive results in
cases of Chagas disease has been documented [15–19]. Addition-
ally, there is an important variation in SLA preparations reflecting
on ELISA sensitivity [14]. Aiming to increase ELISA specificity in
the diagnosis of VL or TL, through the elimination of cross-
reactive epitopes, the use of recombinant Leishmania inmunodo-
minant antigens has been evaluated [20,21]. Many recombinant
antigens have been tested for the serodiagnosis of canine or human
VL [22–24], however, up to date, few recombinant proteins have
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been described as promising for the serodiagnosis of human TL
[25]. In the present study, we employed a large panel of human
sera to test a series of parasite-derived recombinant proteins, using




SLA was prepared from L. infantum-chagasi (MCAN/BR/00/
BA262) promastigotes maintained in Schneider’s medium (Sigma)
supplemented with 10% inactivated fetal bovine serum, 100 U/ml
penicillin and 100 ug/ml streptomycin (Gibco). The parasites
were initially submitted to 10 alternating cycles of freezing and
thawing in liquid nitrogen and water bath and then centrifuged at
16006 g, 4uC for 15 min. The supernatant containing SLA was
collected and protein content quantified using the Micro BCA TM
Protein Reagent Kit assay (Pierce).
Leishmania recombinant proteins
L. infantum-chagasi derived histones [26] and KMP-11 [27] were
expressed and purified as described. L. infantum-chagasi HSP70 was
expressed after BamHI-HindIII cloning of the DNA insert
containing the HSP70 coding region (Acc. Number. X85798)
into the pQE30 prokaryotic expression vector. The DNA insert
was obtained by PCR amplification using oligonucleotides:
forward 59- GCGGATCCATGACATTCGAAGGCGCCAT -39
and reverse 59-GGAAGCTTTTAGTCGACCTCCTC-
GACCTTGG-39 (in italics the additional sequences included for
cloning purposes) and L. infantum (MCAN/ES/96/BCN150) DNA
as template. Recombinant HSP70 was expressed and purified as
described elsewhere [26].
Sera
Samples for the present study were randomly selected from a
serum bank (LIP-CPqGM-FIOCRUZ) built following from
independent studies previously conducted in Northeastern Brazil,
in areas endemic for cutaneous and mucosal Leishmaniasis
[28,29]. The sera panel consisted of 49 sera from Cutaneous
Leishmaniasis (CL) and of 53 sera from Mucosal Leishmaniasis
(ML) patients.
All TL patients had the diagnosis of Leishmaniasis confirmed by
a positive result in at least two of the following tests: Montenegro
skin test, anti-Leishmania serology, histopathology of the lesion or
a therapeutic test. All TL patients came from areas endemic for
TL and presented lesions with clinical characteristics compatible
with either TL or CL what increases the positive predictive values
of immunological and therapeutical tests.
Ethics Statement
All samples used were anonymized. The study was approved by
the Institutional review Board at Centro de Pesquisas Gonc¸alo
Moniz.
Study procedure
To evaluate sensitivity, ELISA was performed as described
below with recombinant proteins (HSP70, H2A, H2B, H3, H4
and KMP11) and results were compared with SLA using the panel
of sera from TL patients The ELISA cut-off value for each product
was established from ROC curves, and calculated by comparison
of the reactivity values from patient’s serum samples and from
normal volunteers (NV) from endemic (n = 39) and non-endemic
(n = 49) areas. Recombinant proteins (HSP70, H2A, H2B, H3, H4
and KMP11) were then tested against a panel of sera from patients
with Chagas disease (n = 30), Systemic Lupus Erythematosus (SLE)
(n = 10), Leprosy (n = 30) and Tuberculosis (n = 22). The resulting
OD values were compared with those obtained with the panel of
TL sera. The epidemiological characteristics of individuals
involved in the study are presented in Table 1.
ELISA to detect anti-Leishmania antibodies
Anti-Leishmania serology was performed by ELISA as described
by [30] with some adaptations. For this, 96-well plates were coated
with SLA (10 ug/mL) or with Leishmania recombinant proteins
(rH2A, rH2B, rH3, rH4, rHSP70 or rKMP11) (1 ug/ml) in
carbonate buffer (0.45 M NaHCO3, Na2CO3, 0.02 M pH 9.6) for
12 h at 4uC. After three washes with PBS-0.5% Tween, the plates
were blocked for 1 hour at 37uC with PBS Tween 0.5% plus 5%
skim milk. Sera were diluted 1:100 in PBS-Tween 0.5% plus 5%
skim milk and incubated for 2 hours at room temperature, under
agitation. After a final round of washing, the wells were incubated
with anti-human IgG conjugated to alkaline phosphatase (Sigma,
Louis, MO) at a 1:2500 dilution in PBS-Tween 0.5% plus 5% skim
milk for 1 hour at room temperature under agitation. Again the
plates were washed and incubated for 30 minutes with a
chromogenic solution of p-nitrophenyl phosphate in sodium
carbonate buffer pH 9.6 with 1 mg/mL of MgCl2. Concentration
of SLA and of recombinant proteins was determined in a dose-
response experiment to evaluate an optimal signal without loss of
specificity (data not shown). In all experiments, the values obtained
were subtracted from those obtained in the background. The
serological experiments were repeated twice yielding similar
results. The tests with the recombinant proteins were conducted
blind with regards to the results obtained with ELISA using SLA.
Statistical analysis
Statistical analysis was performed using Prism 5.0 (GraphPad
Prism Inc., San Diego, CA). Differences in values of antibody
levels between groups were compared using the Kruskal-Wallis
test with Dunn post-test. ROC curves (Receiver Operating
Characteristic) were calculated for each recombinant protein.
The cut-off, as determined by high sensitivity and specificity, from
the highest probability of discrimination established by the curve,
was therefore determined. The performance of each Leishmania
recombinant proteins was established by the parameters obtained
from ROC curves values with AUC, p values and likelihood ratio.
Table 1. Epidemiological characteristics of individuals
involved in the study.
Group
Age [median
(extremes)] Male [n (%)] Female [n (%)]
CL 29.6 (8–72) 30 (61.2) 19 (38.8)
ML 37.8 (12–75) 35 (66) 18 (34.0)
Endemic controls 35.5 (15–65) 20 (51) 19 (49.0)
Non-endemic ctls 33.6 (20–58) 28 (57) 21 (43.0)
Chagas’ disease 39.9 (22–56) 16 (53.3) 14 (46.7)
LES 34.5 (22–66) 0 10 (100)
Leprosy 37.7 (15–75) 13 (43.4) 17(15–75)
Tuberculosis 39.5 (18–85) 14 (63.6) 8 (36.4)
CL = Cutaneous Leishmaniasis; ML = Mucosal Leishmaniasis; Non-endemic
ctls = Non-endemic controls; LES = Lupus Erythematosus Systemic.
doi:10.1371/journal.pone.0066110.t001
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Results
Initially we have evaluated the reactivity of the recombinant
Leishmania proteins against a panel of sera from CL and ML
patients. Overall, sera from ML patients presented a higher
reactivity to the majority of the antigens tested, especially SLA
(Fig. 1A) and rHSP70 (Fig. 1B), compared to CL patients.
Regarding control sera (endemic and non endemic), a few false
positive results were observed both with SLA (Fig. 1A), rHSP70
and rH2A (Fig. 1A–C). The other recombinant proteins show
higher non-specific reaction against natural antibodies of healthy
individuals resulting in a higher number of false positive samples
(Fig. 1D–G). Regarding sera from TL patients (CL and ML), SLA
gave a positive result with 46.9% of CL sera and with 85% of ML
sera (Fig. 1A). Recombinant HSP70 yielded a positive response in
51.9% of CL and in 80% of ML sera (Fig. 1B). Among the
histones, rH2A showed the best results with recognition of 72.2%
of CL and of 56.4% of ML patients’ sera (Fig. 1C). The remaining
recombinant histones, in addition to having a significant number
of false positive samples, were less recognized by sera from CL and
from ML patients (Fig. 1D–F). Despite the recognition of rKMP11
by a significant percentage of sera from CL (55.5%) and ML
(85.1%) patients, this antigen presented a high recognition (85.7%)
by endemic control sera (Fig. 1G).
Based on the ELISA results (Fig. 1), ROC curves were
calculated to evaluate the capacity of SLA and of each
recombinant protein to discriminate TL patients from healthy
volunteers (endemic and non endemic area). Comparisons were
made considering all TL patients as well ML and CL patients,
separately. As shown in Fig. 2A, for TL patients (including ML
and CL patients) the best performances were observed with
rHSP70 (AUC: 0.827, p,0.0001, Likelihood ratio: 8.18) and
rH2A (AUC: 0.789, p,0.0001, Likelihood ratio: 2.31), and by
SLA (AUC: 0.787, p,0.0001, Likelihood ratio: 7.88). The
remaining recombinant proteins (rH2B, rH3, rH4 and rKMP11)
presented lower values for AUC and likelihood ratios. When sera
from ML patients were evaluated, rHSP70 showed the best
performance (AUC: 0.894, p,0.0001, Likelihood ratio: 4.57;
Fig. 2B) when compared to the other recombinant proteins
(Fig. 2B). With CL sera, rH2A showed the best performance
(AUC: 0.808, p,0.0001, Likelihood ratio: 2.52), followed by
rHSP70 (AUC: 0.760, p,0.0001, Likelihood ratio: 2.70) and
rH2B (AUC: 0.676, p = 0.0004, Likelihood ratio: 2.01) (Fig. 2C).
To evaluate the specificity of tests employing recombinant
proteins, serum samples from patients with Chagas disease,
leprosy, tuberculosis or SLE were tested against SLA and each
recombinant antigen. SLA showed high cross-reactivity against
sera from patients with Chagas’ disease (63%), but low cross-
reactivity for sera from SLE (20%), leprosy (3.3%) or tuberculosis
patients (9%) (Fig. 3A). rHSP70 showed the highest reactivity
against sera from SLE (20%) or Chagas’ disease (10%) patients
(Fig. 3B). However, this protein presents lower cross-reactivity
values for tuberculosis (4.5%) or leprosy (3.3%) patients sera
(Fig. 3B). All the histones tested were highly recognized by sera
from SLE patients, especially rH2A which reacted with 100% of
tested sera (Fig. 3C–F). Also, the four Leishmania recombinant
Figure 1. Anti-Leishmania IgG antibodies levels TL patients. Sera from mucosal Leishmaniasis (ML) (n = 53) and cutaneous Leishmaniasis (CL)
(n = 49) patients, and sera from healthy individuals from endemic (n = 39) and from non-endemic (n = 49) areas were tested against SLA (A), rHSP70
(B), rH2A (C), rH2B (D), rH3 (E) rH4 (F) and rKMP11 antigens (G). The cut-off was calculated by comparison of the reactivity values from patient’s serum
samples and from normal volunteers from endemic area and non-endemic areas. The cut-off value for negative and positive samples is indicated in
dotted line. The solid lines represent the median values. Each point represents the mean of the duplicate OD values for the same serum with a
standard deviation lower than 20%. Significance was compared using Kruskal-Wallis test with Dunn’s post test for multiple comparisons. * p,0.05, **
p,0.001 **, p,0.0001.
doi:10.1371/journal.pone.0066110.g001
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Figure 2. ROC curve of antibody levels predict the positivity thresholds against parasite antigens. The ROC curves were constructed
using data obtained in ELISA performed with antigens and sera from TL (n = 102) (A), ML (n = 53) (B) or CL (n = 49) (C) patients and control subjects
from an endemic (n = 39) and from a non-endemic (n = 49) area. The solid lines represent the area under the curve and the dotted line represents the
identity line curves. The tables show the detailed information obtained for each ROC curve (cut-off values chosen, area under the curve, the values of
p, and the sensitivity and specificity with a confidence interval of 95% and the likelihood ratio).
doi:10.1371/journal.pone.0066110.g002
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histones showed cross-reactivity with sera from leprosy patients,
23.4% to rH2A (Fig. 3C), 35.7% to rH2B (Fig. 3D), 6.7% to rH3
(Fig. 3E) and 10% to H4 (Fig. 3F). Likewise, for sera from chagasic
patients, histones presented similar reactivity: 24.1% for rH2A
(Fig. 3C), 26.7% for rH2B (Fig. 3D), 6.7% for rH3 (Fig. 3E) and
23.3% for rH4 (Fig. 3F). Histones also showed low cross-reactivity,
(rH2B [13.6% - Fig. 3D] and rH4 [4.5% - Fig. 3F]) or no cross-
reactivity (rH3 – Fig. 3E) with sera from tuberculosis patients,
except for rH2A where 59% of the samples were recognized
(Fig. 3C). For all the antigens tested, rKMP11 antigen showed
high cross-reactivity, reaching 86.7%, 40%, 18.2% and 20% with
Chagasic, leprosy, tuberculosis and SLE patients’ sera, respectively
(Fig. 3G). Remarkably, rHSP70 showed the best specificity for all
recombinant antigens tested, with similar or lower cross-reactivity
when compared with SLA antigen.
Based on the previous results, we selected SLA (the gold
standard), rH2A (the most reactive histone) and rHSP70 (the best
recombinant protein) to perform ROC curves in order to evaluate
the performance these parasite antigens in their ability to
discriminate patients with Leishmaniasis from those with other
pathologies. ROC curves constructed comparing patients with TL
and other pathologies showed that the best AUC was obtained
with HSP70 (AUC: 0.869, p,0.0001, Likelihood ratio: 7.81)
followed by SLA (AUC: 0.722, p,0.0001, Likelihood ratio: 2.42)
and rH2A (AUC: 0.723, p,0.0001, Likelihood ratio: 1.91)
(Fig. 4A). For sera from ML patients, the best AUC was obtained
using rHSP70 (AUC: 0.922, p,0.0001, Likelihood ratio: 10.42)
followed by SLA (AUC: 0.887, p,0.0001, Likelihood ratio: 3.28)
(Fig. 4B). Also, for sera from CL patients, the highest AUC was
obtained with rHSP70 (AUC: 0.817, p,0.0001, Likelihood ratio:
4.92) followed by rH2A (AUC: 0.734, p,0.0001, Likelihood ratio:
2.12) (Fig. 4C). Among the recombinant proteins tested, rHSP70
presented the best performance, as noted by the parameters
obtained upon ROC analysis, especially regarding the likelihood
ratio presented for this antigen (Fig. 4A–C).
Discussion
In the last decades, an increasing number of recombinant
protein candidates have been proposed to replace the crude
Leishmania antigen (SLA) for the serodiagnosis of leishmaniasis
[24,31–34]. Presently, we decided to test the feasibility of using
recombinant antigens derived from L. infantum-chagasi for the
serodiagnosis of TL. Eventhough these proteins are derived from a
Leishmania species other than L. braziliensis, these proteins belong to
conserved families among the various species of Leishmania [35],
enabling its use for serodiagnosis of TL. In the current study, we
compared six L. infantum-chagasi recombinant proteins and SLA for
the serodiagnosis of TL. We decided to use SLA of L. infantum
chagasi because all recombinant proteins were derived from this
species, and it would not be appropriate to compare with SLA of
another species. Antigens derived from unrelated parasite species
for diagnosis have been used previously for Leishmaniasis
diagnosis [17,36] Several of these proteins have been previously
described as promising antigens for the serodiagnosis to VL but
were yet to assayed against a panel of sera from TL patients.
In general, CL patients had significantly lower anti-Leishmania
antibody titers when compared to sera from ML patients. Higher
Figure 3. Specificity of ELISA employing parasite antigens. Sera from patients with Chagas’ disease (n = 30), SLE (n = 10), leprosy (n = 30) and
tuberculosis (n = 22) were tested against SLA (A), rHSP70 (B), rH2A (C), rH2B (D), rH3 (E) rH4 (F) and rKMP11 antigens (G). The cut-off was established
from the TL ROC curve (Fig. 2) (dotted line). The solid lines represent median values. Each point represents the mean of duplicate values with a
standard deviation lower than 20%.
doi:10.1371/journal.pone.0066110.g003
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antibody response of ML as compared to CL patients has been
reported and may be due to the prolonged course of disease
observed in ML [37,38]. All recombinant proteins were recog-
nized by sera from TL patients (albeit with different OD) and,
among them, rHSP70 presented the best performance in terms of
sensitivity and specificity, being superior to SLA in the diagnosis of
CL. The antigenicity of heat shock proteins in general and that of
HSP70 in particular is not surprising in TL patients, since
antibodies against the parasite recombinant HSPs have been
found in sera of patients with different parasitic diseases [39–41].
In addition, other authors have described that rHSP70 is a
preeminent antigen present in Leishmania [42–46]. Specific
antibodies against L. braziliensis rHSP70 or rHSP83 were found
in 95% of sera from ML or CL patients [47]. Similarly, a high
recognition of rHSP70 by sera of CL [48] or ML patients has been
described [48,49]. However, both studies indicated that sera from
Chagas’ disease patients also gave positive responses albeit with
lower OD values than sera from Leishmaniasis patients. We can
suggest that sensitivity of the ELISA test may explain the lack of
cross reactivity between sera from Chagas’ disease patients and
Figure 4. ROC curve of antibody levels predict the positivity thresholds against rHSP70 and rH2A. ROC curves were constructed using
data obtained with sera from TL (n = 102) (A), ML (n = 53) (B) and CL (n = 49) as patients and sera from individuals with Chagas’ disease (n = 30), SLE
(n = 10), leprosy (n = 30) and tuberculosis (n = 22) as negative control. The solid lines represent the area under the curve and the dotted line
represents the identity line curves. The tables show the detailed information obtained from each ROC curve (cut-off values chosen, area under the
curve, the p values, and the sensitivity and specificity with a confidence interval of 95% and the likelihood ratio).
doi:10.1371/journal.pone.0066110.g004
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rHSP70 in the current report. Presently, the cut off value increased
the accuracy of the ELISA assay, possibly explaining the lower
cross reactivity observed. Lastly, Leishmania rHSP70 has 73% of
sequence identity with its human orthologue [50]. Inspite of this
high degree of sequence conservation, anti-HSP70 antibodies
elicited during Leishmania infection specifically recognize the
parasite rHSP70, without cross-reactivity with the host’s HSP70
[47,51].
We have also tested nucleosomal histones which have been
extensively employed in ELISA against sera from human and
canine VL. In such studies, histones presented a high specificity
and sensitivity and were suggested as useful antigens for VL
serodiagnosis [31,52–55]. The use of histones in the diagnosis of
CL or ML is less studied. The presence of antibodies against L.
peruviana rH2B [25] as well as against L. braziliensis H1 [56] has
been detected in sera from CL patients. In the present study, we
show that the recombinant histones are recognized by a moderate
percentage of sera from ML or CL patients but also presented
moderate cross reactivity with sera from patients from diseases
other than Leishmaniasis, mainly by sera from SLE patients.
Among the four L. infantum-chagasi recombinant histones tested,
rH2A presented better recognition.
In the present report, L. infantum-chagasi rKMP11 presented a
high performance mainly in ML diagnosis, similar to reports with
sera from canine or human VL [46,57–59]. Similar to what had
been previously reported, there was a high reactivity of rKMP-11
with sera from Chagasic patients [60], which limits the role of
KMP-11 in the diagnosis of TL.
Cross-reaction between Leishmania and others diseases caused by
common antigenic determinants hinders specific TL diagnosis
[61], especially in regions where several parasitic diseases are
endemic. Taken together, the data reported here show that
L.infantum-chagasi rHSP70 should be taken into account for the
serodiagnosis of American TL using recombinant antigens.
rHSP70 and rH2A proteins presented sensitivity similar to SLA
(higher in the case of rHSP70). Of note, we have compared the
performance of a combination of rHSP70 plus rH2A in an attempt
to increase sensitivity against sera from CL patients. Serological
analysis and ROC curves using the combined proteins resented a
negligible increase compared to the use of rHSP70 alone.
Furthermore, the ROC curve parameters were lower for sera
from ML patients. On the other hand, the remaining recombinant
antigens (rKMP-11, rH2B, rH3 and rH4) did not satisfactorily
replace SLA due to the lower sensitivity and/or specificity.
Therefore, rHSP70 or, possibly, combinations with different
proteins deserve further evaluation in other endemic areas as a
valuable diagnostic tool for the serodiagnosis of TL.
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